中文名稱(chēng):Ginsenoside Rh4 | 英文名稱(chēng):Ginsenoside Rh4 |
CAS:174721-08-5 | 品牌: 一研 |
保存條件: Store at -20°C | 產(chǎn)品類(lèi)別: 抑制劑 |
Cas : 174721-08-5 |
產(chǎn)品屬性:
產(chǎn)品名稱(chēng) | 規(guī)格 | CAS號(hào) | 型號(hào) |
Ginsenoside Rh4 | 10mM*1mLinDMSO 5mg 10mg | 174721-08-5 | EY-Y0164602 |
Cas No.174721-08-5
別名 N/A
化學(xué)名 N/A
分子式 C36H60O8
分子量 620.86
溶解度 Soluble in DMSO
儲(chǔ)存條件 Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述:
Ginsenoside Rh4 is a rare saponin obtained from Panax notoginseng. Ginsenoside Rh4 activates Bax, caspase 3, caspase 8, and caspase 9. Ginsenoside Rh4 also induces autophagy.
Ginsenoside Rh4 causes cytochrome C release and activates the death receptor Fas, the pro-apoptotic protein Bax, and caspase 3, caspase 8, and caspase 9. Ginsenoside Rh4 induces caspase-dependent apoptosis via both the intrinsic and extrinsic pathways in Caco-2 and HCT-116 cells. The CCK-8 assay reveals that Ginsenoside Rh4 can significantly inhibit the growth of colorectal carcinoma cells, such as Caco-2 and HCT-116 cells, to varying degrees. Ginsenoside Rh4 dramatically reduces cell viability in a concentration- and time-dependent manner. In particular, treatment with 120 and 180 μM Ginsenoside Rh4 results in marked Caco-2 cell death of 44.51±1.23% and 75.74±2.91%, respectively, after incubation for 48 h. Similar results are observed in HCT-116 cells treated with concentrations of 120 μM (33.62±1.98%) and 180 μM Ginsenoside Rh4 (59.88±2.31%). In contrast, concentrations of Rh4 from 120 to 300 μM cause no obvious toxic effects on the normal human colon epithelial cell line CCD-18Co, and a slight difference in the effect is observed between 24 and 48 h of treatment. In the colony formation assay, the number of colonies is found to be significantly decreased in Caco-2 and HCT-116 cells, whereas the number of colonies is almost unchanged in CCD-18Co cells[1].
To assess whether Ginsenoside Rh4 can inhibit the growth of colorectal cancer, a colorectal cancer xenograft model is established by inoculating nude mice with Caco-2 cells. Mice treated with 20 and 40 mg/kg Ginsenoside Rh4 and 40 mg/kg CAMPTO exhibit smaller tumors than the control after 30 days of treatment, showing inhibition rates of 29.91%, 66.30% and 77.82%, respectively. However, there is a significant difference in body weight between the Ginsenoside Rh4-treated group and the CAMPTO-treated group. The body weights of the 20 and 40 mg/kg Ginsenoside Rh4-treated groups (15.95±0.35 g and 18.35±0.44 g) are markedly higher, whereas the body weight of the CAMPTO-treated group is lower (10.85±0.28 g) than that of the solvent control group (14.19±0.25 g)[1].
[1]. Wu Q, et al. Ginsenoside Rh4 induces apoptosis and autophagic cell death through activation of the ROS/JNK/p53 pathway in colorectal cancer cells. Biochem Pharmacol. 2018 Feb;148:64-74.
成立日期 | 2014-06-05 (11年) | 注冊(cè)資本 | 100 |
員工人數(shù) | 50-100人 | 年?duì)I業(yè)額 | ¥ 100萬(wàn)以?xún)?nèi) |
主營(yíng)行業(yè) | 生化試劑,抗體,細(xì)胞培養(yǎng),分子生物學(xué),免疫安全 | 經(jīng)營(yíng)模式 | 工廠,試劑 |
產(chǎn)品名稱(chēng) | 價(jià)格 | 公司名稱(chēng) | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢(xún)價(jià) |
VIP1年
|
湖北萃園生物科技有限公司
|
2025-04-24 | |
¥1000 |
VIP6年
|
成都格利普生物科技有限公司
|
2025-04-23 | |
詢(xún)價(jià) |
VIP7年
|
南京道斯夫生物科技有限公司
|
2025-04-21 | |
¥792 |
VIP3年
|
TargetMol中國(guó)(陶術(shù)生物)
|
2025-02-28 | |
詢(xún)價(jià) |
成都曼思特生物科技有限公司
|
2024-01-23 | ||
詢(xún)價(jià) |
上海西格生物科技有限公司
|
2023-10-27 | ||
詢(xún)價(jià) |
上海撫生實(shí)業(yè)有限公司
|
2023-10-12 | ||
¥1800 |
成都普菲德對(duì)照品科技有限公司
|
2023-05-26 |